A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)
Phase of Trial: Phase IV
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms FINE
- Sponsors Novartis Pharmaceuticals
- 02 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jan 2014 Planned End Date changed from 1 Apr 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 27 Aug 2013 Planned End Date changed from 1 Jan 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.